1. Home
  2. CINGW vs HCSG Comparison

CINGW vs HCSG Comparison

Compare CINGW & HCSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • HCSG
  • Stock Information
  • Founded
  • CINGW N/A
  • HCSG 1976
  • Country
  • CINGW United States
  • HCSG United States
  • Employees
  • CINGW 13
  • HCSG N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • HCSG Assisted Living Services
  • Sector
  • CINGW Health Care
  • HCSG Health Care
  • Exchange
  • CINGW Nasdaq
  • HCSG Nasdaq
  • Market Cap
  • CINGW N/A
  • HCSG N/A
  • IPO Year
  • CINGW 2021
  • HCSG N/A
  • Fundamental
  • Price
  • CINGW $0.05
  • HCSG $10.45
  • Analyst Decision
  • CINGW
  • HCSG Buy
  • Analyst Count
  • CINGW 0
  • HCSG 4
  • Target Price
  • CINGW N/A
  • HCSG $14.50
  • AVG Volume (30 Days)
  • CINGW N/A
  • HCSG 347.3K
  • Earning Date
  • CINGW N/A
  • HCSG 10-23-2024
  • Dividend Yield
  • CINGW N/A
  • HCSG N/A
  • EPS Growth
  • CINGW N/A
  • HCSG N/A
  • EPS
  • CINGW N/A
  • HCSG 0.43
  • Revenue
  • CINGW N/A
  • HCSG $1,684,949,000.00
  • Revenue This Year
  • CINGW N/A
  • HCSG $4.64
  • Revenue Next Year
  • CINGW N/A
  • HCSG $3.14
  • P/E Ratio
  • CINGW N/A
  • HCSG $24.40
  • Revenue Growth
  • CINGW N/A
  • HCSG 0.61
  • 52 Week Low
  • CINGW N/A
  • HCSG $8.75
  • 52 Week High
  • CINGW N/A
  • HCSG $13.00
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • HCSG 47.20
  • Support Level
  • CINGW N/A
  • HCSG $10.54
  • Resistance Level
  • CINGW N/A
  • HCSG $10.91
  • Average True Range (ATR)
  • CINGW 0.00
  • HCSG 0.27
  • MACD
  • CINGW 0.00
  • HCSG 0.05
  • Stochastic Oscillator
  • CINGW 0.00
  • HCSG 61.98

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: